We are live on
!
Find out more
B
Braidwell Portfolio holdings
AUM
$3B
1-Year Est. Return
46.72%
This Fund
S&P 500
This Quarter
Est. Return
+10.55%
1 Year Est. Return
+46.72%
3 Year Est. Return
+56.07%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.37B
AUM Growth
+$446M
(+15%)
Cap. Flow
-$654M
Cap. Flow
% of AUM
-19.4%
Top 10 Holdings %
Top 10 Hldgs %
44.1%
Holding
79
New
25
Increased
8
Reduced
18
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLNO
Soleno Therapeutics
SLNO
|
+$95M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
+$56.3M |
| 3 |
HNGE
Hinge Health
HNGE
|
+$47.6M |
| 4 |
Inspire Medical Systems
INSP
|
+$36.6M |
| 5 |
CareDx
CDNA
|
+$31.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$78.1M |
| 2 |
Guardant Health
GH
|
+$43.6M |
| 3 |
Adaptive Biotechnologies
ADPT
|
+$38.1M |
| 4 |
Neurocrine Biosciences
NBIX
|
+$38M |
| 5 |
Krystal Biotech
KRYS
|
+$31M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 73.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Encompass Health
EHC
$11.2B
| $14.4M | 0.43% |
+113,335
| New | +$13.5M |
|
52
Vera Therapeutics
VERA
$2.54B
| $13.7M | 0.41% |
+472,739
| New | +$10.9M |
|
53
NeoGenomics
NEO
$1.81B
| $13.7M | 0.41% |
+1,771,146
| New | +$12.4M |
|
|
TECX
54
Tectonic Therapeutic
TECX
$573M
| $11.6M | 0.34% |
+736,867
| New | +$15.2M |
|
55
Replimune Group
REPL
$814M
| $11.5M | 0.34% |
2,750,092
+2,327,205
| +550% | +$14.9M |
|
|
56
Adaptive Biotechnologies
ADPT
$3.56B
| $11M | 0.33% |
736,014
-3,127,093
| -81% | -$38.1M |
|
57
Zura Bio
ZURA
$497M
| $10.7M | 0.32% |
2,472,806
| – | – |
|
|
SION
58
Sionna Therapeutics
SION
$2.06B
| $9.24M | 0.27% |
314,013
-767,842
| -71% | -$16.7M |
|
59
Amylyx Pharmaceuticals
AMLX
$2.05B
| $8.33M | 0.25% |
+612,841
| New | +$5.77M |
|
60
Royalty Pharma
RPRX
$26.1B
| $6.42M | 0.19% |
+182,068
| New | +$6.59M |
|
61
Fulcrum Therapeutics
FULC
$248M
| $2.02M | 0.06% |
+219,488
| New | +$1.59M |
|
62
Surrozen
SRZN
$229M
| $1.8M | 0.05% |
140,000
| – | – |
|
|
HTFL
63
Heartflow Inc
HTFL
$2.08B
| $1.68M | 0.05% |
+50,000
| New | +$1.61M |
|
64
Pulmonx
LUNG
$49.4M
| $1.22M | 0.04% |
752,541
| – | – |
|
|
APLS
65
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-1,121,034
| Closed | -$19.4M |
|
66
Celcuity
CELC
$4.03B
| – | – |
-884,306
| Closed | -$11.8M |
|
|
67
Guardant Health
GH
$19.5B
| – | – |
-837,800
| Closed | -$43.6M |
|
|
CBIO
68
Crescent Biopharma
CBIO
$602M
| – | – |
-261,504
| Closed | -$4.22M |
|
69
Madrigal Pharmaceuticals
MDGL
$12.6B
| – | – |
-60,781
| Closed | -$18.4M |
|
70
UnitedHealth
UNH
$382B
| – | – |
-49,400
| Closed | -$15.4M |
|
Similar funds
NC
SGI
SP
DIG
PCM
VVP
ROTUOC
PHAM
Braidwell's Q3 2025 Portfolio in Review
As of Q3 2025, Braidwell held 79 positions worth $3.37B, up 15% from $2.92B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Braidwell withdrew a net $654M in Q3 2025, closing 6 positions and reducing 18 holdings. Its most notable exit was Guardant Health, an estimated $43.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 72% a quarter earlier.
Against the trend, Braidwell opened a new position in Soleno Therapeutics worth $86.7M.
- Braidwell's largest Q3 2025 buy was Soleno Therapeutics: 1,281,989 shares worth $86.7M.
- Braidwell added most to Inspire Medical Systems in Q3 2025, an estimated $36.6M increase.
- Braidwell's biggest Q3 2025 reduction was argenx, cutting an estimated $78.1M.
- Braidwell fully exited Guardant Health in Q3 2025, selling an estimated $43.6M.
- Braidwell's ten largest holdings make up 44% of its $3.37B portfolio in Q3 2025.
- Braidwell opened 25 new positions and closed 6 in Q3 2025.
- Braidwell's portfolio value rose 15% quarter-over-quarter to $3.37B.
Based on Braidwell's 13F filing for Q3 2025, filed 14 Nov 2025.